• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300357.SZ
Share

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Stocks

CN¥ 24.01Last Updated 10.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.86B

CN¥ 24.01
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. operates as a biopharmaceutical enterprise, primarily engaged in the discovery, development, production, and sale of medicinal products. The company's core focus is on pharmaceuticals designed for the diagnosis and management of allergic conditions, which it supplies to both the Chinese domestic market and international clientele. Additionally, its portfolio encompasses various skincare lines and stem cell-related solutions. The firm's main offices are located in Huzhou, China.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'ex

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 300357.SZ is 38.3 and suggests 61.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.07.2026 11:45

Wall Street's New Leaders: Who Will Succeed Buffett and Dalio?

13.07.2026 11:04

Oil prices approached $80 per barrel amid renewed tensions between the U.S. and Iran

13.07.2026 10:37

Morning Highlights: Oil Rises 4%, Gold and Bitcoin Fall, SK Hynix Pulls Back

13.07.2026 10:29

Inflation in the U.S. and Europe, Banks, and TSMC: What Investors Need to Know This Week

12.07.2026 21:00

SK Hynix's Debut, Shein's New Plan, and Logistics Companies from Uzbekistan: Key IPO Updates as of July 12

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026